The First Interventional Precision Medicine Trial for Cardiovascular Disease
DalCor is conducting dal-GenE (DAL-301), the first interventional precision medicine cardiovascular outcomes trial. This Phase 3 clinical trial is evaluating the efficacy of dalcetrapib versus placebo to reduce clinical cardiovascular events in 6150 patients post-ACS who carry the ADCY9 rs1967309 AA genotype.
Enrollment for the dal-GenE clinical trial was completed in December 2018 and the results are expected in the first half of 2021.
For more information about the dal-GenE study, please visit clinicaltrials.gov and access NCT02525939.